Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, has been gaining from its continued product ...

(MENAFN- GlobeNewsWire - Nasdaq) PacBio's Revio system and SPRQ-Nx chemistry to enable an order-of-magnitude expansion of HiFi metagenomic sequencing for scaling AI-designed therapeutics MENLO PARK, ...

Explore how advances in accuracy, throughput and cost are making long-read sequencing more accessible at scale.

Detailed price information for Pacific Biosciences (PACB-Q) from The Globe and Mail including charting and trades.

Earlier this year, PacBio announced a collaboration with global rare disease genomics program iHope (part of the Genetic ...

What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones ...

Rapid expansion in clinical applications, rising demand for genomic diagnostics, and increased investment in CRISPR-based ...

Investing.com - Canaccord Genuity reiterated a Buy stock rating and $3.00 price target on Pacific Biosciences of California (NASDAQ:PACB) shares. The stock currently trades at $1.33, representing ...

Brian Tait calls for public support to fund exciting groundbreaking technology for assigning phase to multiple mutations ...

Evolution works over millennia. Climate change is moving far faster. That mismatch is killing some of the planet’s most vital ...

The market misinterprets past COVID-era revenue growth for 10x Genomics and fails to integrate current sector growth. Read why TXG stock is a Buy.

GRAIL, Inc. GRAL recently announced a strategic collaboration with Epic to integrate its Galleri multi-cancer early detection ...